Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RGLS 4326

Next Previous
Drug Profile

RGLS 4326

Alternative Names: RGLS-4326

Latest Information Update: 14 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MIRN17 microRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal dominant polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autosomal dominant polycystic kidney disease

Most Recent Events

  • 12 Nov 2021 Regulus Therapeutics completes a phase I trial in Autosomal dominant polycystic kidney disease (In adults, In the elderly) in USA (SC) (NCT04536688)
  • 13 Oct 2021 Discontinued - Phase-I for Autosomal dominant polycystic kidney disease (In the elderly, In adults) in USA (SC)
  • 10 Aug 2021 Regulus plans to discuss its approach for the remaining partial clinical hold requirements with US FDA for IND in Autosomal dominant polycystic kidney disease in the third quarter of 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top